CFDA Accepts HCV Treatments from Seven Companies for Accelerated Approval

In a bid to speed approval of improved treatments for hepatitis C, China's FDA has granted priority review to HCV drug candidates from seven pharmas. Four of these companies are international big pharmas. The other three consist of Ascletis Pharma from Hangzhou, Beijing Kawin Technology and Taiwan's TaiGen Biopharma. Previously, the CFDA has not accepted foreign drugs into the Green Channel, the unofficial name of the accelerated process. It is also the first time a group of drugs targeting the same condition have been simultaneously accepted for a prioritized review. More details....

Share this with colleagues: